Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.67 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | FABP3 | P05413 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | PTAFR | P25105 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482557 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL29876392 | 0.96 | ALDH1A1 (0.71) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL30653594 | 0.96 | ALDH1A1 (0.71) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL29876809 | 0.95 | ALDH1A1 (0.70) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL19864321 | 0.95 | ALDH1A1 (0.70) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL30651167 | 0.95 | ALDH1A1 (0.70) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL30649867 | 0.94 | ALDH1A1 (0.72) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL31616183 | 0.94 | ALDH1A1 (0.72) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL29812971 | 0.94 | ALDH1A1 (0.75) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT | |
| SCHEMBL30652068 | 0.94 | ALDH1A1 (0.72) | SMN1; SMN2NR5A2NR5A1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144803-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | EDEN OPHTHALMIC PTE LTD. (SG) | 2026-05-28 | — | — | US | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743094-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | Eden Ophthalmic Pte Ltd. (SG) | 2026-05-20 | — | — | EP | claimed |
| WO-2026090328-A1 | WNT7a MRNA LIPID NANOPARTICLES FOR THERAPEUTIC USES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4724419-A1 | A NANOPARTICLE COMPOSITION AND RELATED METHODS THEREOF | Agency for Science, Technology and Research (SG) | 2026-04-15 | — | — | EP | claimed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4709361-A1 | A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF | Agency for Science, Technology and Research (SG) | 2026-03-18 | — | — | EP | claimed |
| EP-4695385-A1 | GENE EDITING FOR INTERVERTEBRAL, INTRA- AND PERIDISCAL THERAPY AND ASSOCIATED SPINAL DISORDERS | Orthobio Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4694913-A2 | LIPID NANOPARTICLES FOR GENE EDITING SYSTEMS | Orthobio Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4106828-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | GIE Medical, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | claimed |
| WO-2022204288-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4036079-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ModernaTX, Inc. (US) | 2022-08-03 | — | — | EP | claimed |
| EP-4025556-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | Guangzhou Ribobio Co., Ltd (CN) | 2022-07-13 | — | — | EP | claimed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022112855-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | Guangzhou Ribobio Co., Ltd (CN) | 2022-06-02 | — | — | WO | claimed |
| EP-3965745-A1 | METHODS OF USING LIPID NANOPARTICLES FOR DELIVERING MODIFIED RNA ENCODING A VEGF-A POLYPEPTIDE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | AstraZeneca AB (SE) | 2022-03-16 | — | — | EP | claimed |
| EP-2444464-A1 | Novel neutral (bio)material | Centre National de la Recherche Scientifique (CNRS) (FR) | 2012-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144803-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | STARD3, STARD7, PHOSPHO1 | SMN1; SMN2 3764/4885NR5A2 912/4885NR5A1 167/4885 |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | EXOSC5, EXOSC4, EXOSC10 | SMN1; SMN2 1847/4885NR5A2 4354/4885NR5A1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.